Y.S.P. Southeast Asia Holding Berhad Valuation

Q: What is the Fair Price of YSPSAH when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

YSPSAH (MYR2.27) is trading below our estimate of [[fair value]] (MYR4.04)

Is YSPSAH undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

4/6

Valuation Score 4/6

Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of YSPSAH when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: YSPSAH (MYR2.27) is trading below our estimate of fair value (MYR4.04)

Significantly Below Fair Value: YSPSAH is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for YSPSAH?

Key metric: As YSPSAH is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for YSPSAH. This is calculated by dividing YSPSAH's market cap by their current earnings.
What is YSPSAH's PE Ratio?
PE Ratio	11.2x
Earnings	RM 28.65m
Market Cap	RM 321.99m

YSPSAH key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	0.7x
Enterprise Value/EBITDA	4.8x
PEG Ratio	n/a

Price to Earnings Ratio vs Peers

How does YSPSAH's PE Ratio compare to its peers?

The above table shows the PE ratio for YSPSAH vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PE	Estimated Growth	Market Cap
Peer Average	17.1x
KOTRA Kotra Industries Berhad	14.4x	8.1%	RM 642.2m
RHONEMA Rhone Ma Holdings Berhad	12x	5.8%	RM 149.3m
DPHARMA Duopharma Biotech Berhad	21.3x	23.0%	RM 1.2b
AHEALTH Apex Healthcare Berhad	20.8x	9.4%	RM 1.9b
YSPSAH Y.S.P. Southeast Asia Holding Berhad	11.2x	n/a	RM 322.0m

Price-To-Earnings vs Peers: YSPSAH is good value based on its Price-To-Earnings Ratio (11.2x) compared to the peer average (17.1x).

Price to Earnings Ratio vs Industry

How does YSPSAH's PE Ratio compare vs other companies in the Asian Pharmaceuticals Industry?

12 Companies	Price / Earnings	Estimated Growth	Market Cap

12 Companies		Estimated Growth	Market Cap

No more companies

Price-To-Earnings vs Industry: YSPSAH is good value based on its Price-To-Earnings Ratio (11.2x) compared to the Asian Pharmaceuticals industry average (24.6x).

Price to Earnings Ratio vs Fair Ratio

What is YSPSAH's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

YSPSAH PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio	11.2x
Fair PE Ratio	n/a

Price-To-Earnings vs Fair Ratio: Insufficient data to calculate YSPSAH's Price-To-Earnings Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.